NMTR Projected Dividend Yield
9 Meters Biopharma Inc ( NASDAQ : NMTR )9 Meters Biopharma is a clinical-stage company focusing on the treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Co. is deveoping its primary product candidate, vurolenatide for the treatment of SBS, as well as NM-136 for rare obesity disorders. Co. is also developing NM-003 and NM-102 for the treatment of undisclosed rare debilitating digestive diseases with unmet needs and larazotide for the treatment of Multi-system Inflammatory Syndrome through a collaboration with the European Biomedical Research Institute of Salerno, Italy. 20 YEAR PERFORMANCE RESULTS |
NMTR Dividend History Detail NMTR Dividend News NMTR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |